Brexit Good For UK Firms And Emerging Markets?
This article was originally published in PharmAsia News
Executive Summary
Despite creating shockwaves around the globe, the UK’s ‘Brexit’ vote to leave the EU is expected by analysts to positively impact European pharma companies such as GSK, Sanofi and AstraZeneca. But the impact on product sales and emerging markets will be more of a mixed bag.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.